* Takes EU stock of potential COVID-19 shots to almost 2 bln
* Sixth deal struck with COVID-19 vaccine developers
* Price, delivery timetable not disclosed
(adds context)
By Francesco Guarascio
BRUSSELS, Nov 24 (Reuters) - The European Union has struck a
deal for up to 160 million doses of U.S. firm Moderna's
COVID-19 vaccine candidate, the head of the European Commission
said on Tuesday, taking the EU's potential stock of COVID-19
shots to nearly 2 billion.
Last week, Moderna said its experimental vaccine was 94.5%
effective in preventing COVID-19, based on interim data from a
late-stage clinical trial.
"I am happy to announce that tomorrow we will approve a new
contract to secure another COVID-19 vaccine," Ursula von der
Leyen said, adding the deal "allows us to buy up to 160 million
doses of a vaccine produced by Moderna."
Actual purchases will be carried out by EU governments if
the vaccine is approved by the EU's drug regulator.
The delivery timeline is unknown. The doses would be enough
to vaccinate 80 million people as the vaccine is expected to be
administered in two doses.
In August the EU's executive Commission, which co-leads
talks with vaccine makers on behalf of member states, said it
had held preliminary talks with Moderna over a deal for 80
million doses and an option for 80 million more.
The terms of the contract have not been disclosed.
An EU official involved in the talks told Reuters last week
the EU was seeking a price below $25 per dose for Moderna's
vaccine..
But Moderna Chief Executive Stephane Bancel said on Sunday
the company would charge governments between $25 and $37 per
dose, depending on the amount ordered.
A spokesman for the Commission declined to comment on
pricing.
It is the sixth supply deal the EU has negotiated with
COVID-19 vaccine makers and takes the total number of doses
secured by the bloc to 1.96 billion for its population of around
450 million.
Brussels has already struck deals with AstraZeneca,
Pfizer-BioNTech, Sanofi-GSK, Johnson & Johnson and CureVac.
It is also in talks to buy U.S. firm Novavax's potential
COVID-19 vaccine.
(Reporting by Francesco Guarascio @fraguarascio
Editing by Alexandra Hudson and Mark Potter)
Astrazeneca (AZN)
